NeuShen Therapeutics, a Shanghai and Boston biotech, raised more than $80 million in a Series B round to advance three clinical-stage brain-health drugs. The funding underscores continued investor demand for late-stage translational neurology assets amid heightened competition for novel CNS mechanisms. With multiple programs in flight, NeuShen’s capital allocation will likely focus on clinical execution and evidence generation needed for regulatory milestones. For the sector, the round also signals that brain-health remains an investable therapeutic category even as investors increasingly demand clear clinical differentiation. The deal adds to a broader financing pattern: companies with defined clinical-stage pathways are attracting larger rounds as the market prioritizes near-term data visibility.